Neotherix

What Neotherix does

Neotherix Ltd is a York, UK-based regenerative medicine company founded in 2007 as a spin-out from Smith & Nephew to develop bioresorbable tissue scaffolds for problem wound applications. The company applies electrospinning technology — using high-voltage electric fields to create polymer fibre networks between 10nm and 10µm — to produce highly porous, bioresorbable scaffolds that degrade by hydrolysis and provide 3D architecture enabling the patient's own cells to repopulate and regenerate wound spaces. Its portfolio comprises four products addressing distinct clinical indications: EktoTherix™ (enhanced repair of acute and surgical wounds), Seton-Scaffold Device™ (combined drainage and tissue repair for fistula-in-ano), RegeniTherix™ (theranostic system pairing therapeutic scaffold with diagnostic hydrogel for chronic wound biomarker monitoring, including IL-6 and TNF-α detection), and PhotoTherix™ (photodynamically active fibres delivering on-demand antimicrobial action to reduce antibiotic dependency in high-infection-risk procedures).

The company holds ISO 13485 certification (2016) for Class III medical device manufacture, two granted patents covering its wound sampling technology (US 10,687,790 and EP 2765921), and registered trademarks across its product portfolio. Strategic partners include the NIHR (over £2M in cumulative i4i grant funding), Innovate UK, University of York, University of Birmingham, and University Hospitals Birmingham NHS Trust, with Chief Investigator Professor Tom Pinkney leading the Seton-Scaffold Device pivotal study.

Neotherix operates a B2B MedTech business model targeting NHS trusts and healthcare institutions through direct hospital sales and enterprise field engagement. Revenue is expected to come from medical device hardware sales, though the company is currently pre-commercial with no disclosed revenue and pricing conducted via quote-based NHS procurement. Operations are led by Founder/CEO Dr Mike Raxworthy, Chairman Dr Rod Adams, and Operations Director Dr Clare Lankester, with a small team of 1-10 employees based at the Hiscox Building in York.

Name

Neotherix

Legal name

Neotherix Ltd

Website

https://neotherix.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Neotherix is a York, UK-based regenerative medicine company developing electrospun bioresorbable scaffolds for problem wound applications across acute, chronic, fistula, and antimicrobial indications. The pre-commercial MedTech sells Class III medical devices to NHS trusts and healthcare institutions via direct hospital sales.

Ownership category

akta.pro rank

Product category

Wound Care Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

akta.pro secondary industries

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

Keywords

• Bioresorbable scaffolds
• Regenerative medicine
• Electrospinning technology
• Wound healing devices
• Tissue repair scaffolds

Headquarters

HQ city

York

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Pre-commercial stage company developing bioresorbable scaffold medical devices for tissue repair. Revenue will come from sales of medical devices to healthcare providers and clinical institutions for wound care applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Neotherix develops and manufactures bioresorbable tissue repair scaffolds using proprietary electrospinning technology. Its product portfolio targets problem wounds including acute and surgical wounds (EktoTherix), fistula-in-ano (Seton-Scaffold Device), chronic wounds with theranostic monitoring (RegeniTherix), and infected wounds (PhotoTherix). The company sells Class III medical devices primarily to NHS hospitals and clinical institutions in the UK.

Product overview

Neotherix is a MedTech company developing bioresorbable scaffold products for tissue regeneration and repair using electrospinning technology. The product portfolio consists of four distinct products: EktoTherix™ (tissue repair scaffold for acute and surgical wounds), Seton-Scaffold Device™ (fistula-in-ano treatment combining drainage and repair), RegeniTherix™ (theranostic system for wound monitoring through biomarker detection), and PhotoTherix™ (antimicrobial wound scaffold activated by light). These products address problem wounds including acute wounds, chronic wounds, infected wounds, and fistulas/tracts.

Differentiator

Problem solved

Functional benefit

Brands

• EktoTherix™: Tissue repair scaffold made of electrospun fibres for enhanced repair of acute and surgical wounds. Bioresorbable scaffold that degrades by hydrolysis and is resorbed during the healing process.
• PhotoTherix™
• RegeniTherix™
• Seton-Scaffold Device™

Products and services

• EktoTherix™ Bioresorbable tissue repair scaffold made from electrospun fibres for enhanced repair of acute and surgical wounds; promotes granulation tissue formation and is resorbed during healing via hydrolysis. Designed for healthcare providers such as NHS consultants treating wounds that cannot be closed by primary intention.
• Seton-Scaffold Device™ Novel bioresorbable scaffold device combined with a seton for treatment of fistula-in-ano (and applicable to pilonidal sinuses); enables simultaneous active drainage and tissue regrowth to heal the fistula tract. Targeted at colorectal surgeons treating the over 12,000 annual UK cases of anal fistula.
• RegeniTherix™ Theranostic system combining a therapeutic scaffold with a thermally switchable diagnostic hydrogel for non-invasive wound biomarker collection and sampling; enables combined healing and monitoring of chronic wounds, including detection of IL-6 and TNF-α at clinically relevant concentrations.
• PhotoTherix™ Light-activated wound scaffold using photodynamically active fibres (PAFs) that release antimicrobial activity on-demand via photodynamic therapy, providing antimicrobial action without contributing to antimicrobial resistance. Designed for periodontal or dermal wound applications at high risk of infection.

Quantifiable outcome

• First-in-man study demonstrated safety and potential for improved healing with EktoTherix in 15 patients
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• University of YorkcoreStrategic or Co-development PartnerResearch collaboration on RegeniTherix biomarker detection technology. Fundamental research on theranostic system published in Biosensors and Bioelectronics.
• University of BirminghamcoreStrategic or Co-development PartnerAcademic partner in Seton-Scaffold Device consortium working on clinical development.
• University Hospitals Birmingham NHS TrustcoreStrategic or Co-development PartnerClinical partner leading the Seton-Scaffold Device development. Professor Tom Pinkney serves as Chief Investigator. Queen Elizabeth Hospital Birmingham involved in clinical studies.
• Keighleycolo LtdcoreStrategic or Co-development PartnerIndustry partner in Seton-Scaffold consortium. Professor Mike Keighley provides clinical expertise in colorectal disease.
• University of East Anglia (UEA)minorStrategic or Co-development PartnerResearch collaboration on rapid immobilisation of protein on polyester microcarriers using click chemistry. Research published in Bioconjugate Chemistry.
• Regener8minorStrategic or Co-development PartnerPart of Medical Technologies IKC community of academics, clinicians and industry collaborators. Funded PhotoTherix development.
• BionowminorStrategic or Co-development PartnerIndustry organization member. Bionow recognized the Seton-Scaffold project with award nomination and awarded RegeniTherix Project of the Year 2015.
• Medical Technologies IKCcoreStrategic or Co-development PartnerInnovation and Knowledge Centre supporting medical technology translation. Mike Raxworthy has connections to this community and Regener8.
• White Rose University ConsortiumminorStrategic or Co-development PartnerUniversity consortium member supporting research and development activities.
• Bradford UniversityminorStrategic or Co-development PartnerAcademic partner involved in consortium activities and collaborations.
• City of York CouncilminorStrategic or Co-development PartnerLocal government partner supporting the innovation ecosystem.
• MedilinkminorGTM or Marketing PartnerHealthcare business organization member providing networking and partnership development support.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Coloplast: Coloplast's Wound & Skin Care division offers a broad portfolio of advanced wound dressings and skin substitutes (e.g., Biatain, Omnistrip) targeting chronic and surgical wounds, providing a useful incumbent benchmark for commercial scaling in advanced wound care.
• Smith & Nephew: Smith & Nephew is Neotherix's former parent company and a global leader in advanced wound care (Allevyn, PICO, OASIS), with active R&D in bioresorbable and regenerative wound technologies — directly relevant as both the licensor of Neotherix's core technology and a likely competitive benchmark.
• Integra LifeSciences: Integra LifeSciences has a dedicated wound care and regenerative tissue portfolio including dermal regeneration templates (Integra Dermal Regeneration Template) and amniotic membrane products, competing across Neotherix's wound regeneration indications from a much broader medtech platform.
• Mölnlycke Health Care: Mölnlycke is a leading global wound care and surgical solutions provider (Mepilex, Mepitel, Avance), with growing investment in regenerative and bioresorbable wound technologies, making it a relevant broad incumbent comparable for Neotherix's portfolio.
• Convatec: Convatec is one of the four largest global advanced wound care companies, offering a portfolio of dressings, negative pressure wound therapy, and skin substitutes (e.g., InnovaMatrix) that compete with Neotherix's scaffold products across acute, chronic, and surgical wound indications.

Emerging players

• ACell: ACell develops and markets MatriStem urinary bladder matrix-based wound care products for complex wounds and soft tissue repair, providing an emerging player comparable to Neotherix in the regenerative wound scaffold segment.
• Aroa Biosurgery: Aroa Biosurgery develops regenerative soft tissue repair products derived from ovine forestomach matrix (Endoform, Myriad), competing in the same biological scaffold space for soft tissue and wound healing, with comparable scale and stage to Neotherix.

Direct peers

• MiMedx: MiMedx develops and commercialises regenerative wound healing products derived from placental tissue (EpiFix, AmnioFix) for chronic and acute wounds, addressing the same wound healing indications (diabetic foot ulcers, surgical wounds) targeted by Neotherix's scaffold platform.
• Organogenesis: Organogenesis markets advanced wound care products including cellular and acellular skin substitutes and regenerative tissue technologies (e.g., Apligraf, Dermagraft), competing in the same regenerative wound healing space Neotherix targets with its bioresorbable scaffolds.
• PolyNovo: PolyNovo develops and commercialises bioabsorbable synthetic scaffolds (NovoSorb BTM) for wound and dermal regeneration using a similar bioresorbable polymer approach to Neotherix's electrospun scaffolds, making it the closest listed direct peer in technology and application.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neotherix